The fifth batch of national procurement catalogs with a large number of purchases were released, and 60 varieties were shortlisted as the most centralized procurement ever

Reporter | Yuan Yiming

Edit | Xie Xin

On April 15, the industry issued a "Notice on Reporting the Purchasing Data of the Fifth Batch of Nationally Organized Drug Centralized Procurement Varieties" (hereinafter referred to as the "Notice") issued by the Joint Procurement Office of National Organization of Drugs
.

The list of drugs procured in quantity published in the "Notice" shows that the fifth round of procured quantities in quantity involves 60 varieties and 207 product specifications

In terms of the specific implementation timetable, the "Notice" requires that provinces can conduct volume reporting operation tests through the system before 24:00 on April 18 this year, and the volume reporting will be officially launched on April 19.
Each province chooses medical institutions to report directly or provincial representatives.
Report method, fill in the pre-purchase quantity of relevant drugs, and complete it before 24:00 on April 30
.

All provinces will complete the review of pre-purchasing quantities of medicines before 17:00 on May 12, export and print them together, affix the official seal of the Provincial Medical Insurance Bureau, and submit the electronic files and scanned copies to the Joint Procurement Office by the system

According to previous industry news, the fifth batch of national procurement will be completed before July 1, and the list of catalogues will be announced at the present time
.

This progress is also in line with the previously circulated time requirements .

Among the most closely watched shortlisted products, a total of 207 products with specifications were shortlisted this time
.

Including chemotherapy drugs, digestive agents, antibiotics, respiratory, inhalation formulation, the contrast agent, a diabetes drug, an adjuvant, related ophthalmic drugs, antiviral drugs and the like

It is worth noting that there are as many as 30 injections among the 60 varieties this time, reaching half of them
.

In terms of specific varieties, antibiotics account for a higher proportion in this batch of lists, involving 30 product regulations, including azithromycin, cefuroxime, ceftriaxone, ceftazidime, etc.

In addition, not all the varieties collected this time met the conditions of consistency evaluation of more than two companies, such as olopatadine hydrochloride, benazepril hydrochloride, budesonide suspension for inhalation, isosorbide mononitrate sustained-release tablets, At present, only two of more than ten varieties, such as iohexol injection and dutasteride soft capsules, have been reviewed, and this also means that the intensity of centralized procurement has been further accelerated
.

From the perspective of the manufacturers involved, AstraZeneca is the foreign-funded pharmaceutical company with the largest variety of shortlisted products.
Its injections, esomeprazole sodium, budesonide suspension for inhalation, metoprolol tartrate, and saxagliptin Many well-known varieties were shortlisted, Sanofi's two major tumor products, oxaliplatin and docetaxel, were shortlisted for Bayer's core anticoagulant drug rivaroxaban, and Fresenius Kabi was shortlisted for multiple anesthetic varieties
.

In terms of domestic enterprises, over 10 products including Chia Tai Tianqing, Chia Tai Fenghai, and Beijing Tide under Sino Biopharmaceuticals are shortlisted, and they are still the “big players” in this centralized procurement.
In addition, Hengrui Pharmaceutical’s main products in the imaging sector are iohexol and iodine.
Extensol was shortlisted (produced by Stellite), Qilu Pharmaceutical, CSPC, Yangzijiang Pharmaceutical, Huahai Pharmaceutical, Xinlitai and other major domestic traditional generic pharmaceutical manufacturers also have multiple varieties selected
.

It is worth mentioning that the thymus method for injection, which has long been regarded as an "adjuvant drug", is also shortlisted for collection this time, and the original manufacturer is Saisheng Pharmaceutical

In accordance with the requirements of the State Council issued by the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs issued by the General Office of the State Council on January 28, the scope of drugs purchased in quantities should be in accordance with the requirements The principle of basic and clinical protection, focusing on including drugs with large amounts and high purchase amounts in the basic medical insurance drug catalog, gradually covering all kinds of clinically necessary and reliable drugs on the market in China, so that all drugs should be collected
.

In addition, on March 5, the Medical Insurance Bureau and the Department of Recruitment and Procurement and representatives of 11 provinces and cities including Tianjin, Shanghai, Chongqing and other joint procurement offices organized a drug centralized procurement work conference in Nanjing.
The main content was to explore the development of special drug procurement and study national belts.
Renew the contract after the expiration of the quantity purchased products, and improve the selection rules of the national drug collection plan
.

According to industry news, the conference mainly released the following four aspects:

The country will carry out special procurement with quantities, and the first batch of test water varieties will be insulin
.

Products that belong to the category of biological preparations will not be included in this special purchase for the time being;

1. For the "4+7" contract renewal issue, the state will delegate power to local governments and point out the overall guiding principles